Advertisement
Screener

Aptevo Therapeutics Inc. (APVO) Increase (Decrease) in Accounts Payable and Accrued Liabilities

2.8 / 5 stars · 68/120 Roast Me

Aptevo Therapeutics Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities

Aptevo Therapeutics Inc. (APVO) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$157.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-03-26

  • Aptevo Therapeutics Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $434.00K, a 33.95% increase year-over-year.
  • Aptevo Therapeutics Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $724.00K, a 56.03% increase year-over-year.
  • Aptevo Therapeutics Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-06-30 was -$501.00K.
  • Aptevo Therapeutics Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-03-31 was -$814.00K.
  • Aptevo Therapeutics Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was -$157.00K.
  • Aptevo Therapeutics Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was -$1.02M, a 296.33% decline from fiscal 2023.
  • Aptevo Therapeutics Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $518.00K.
  • Aptevo Therapeutics Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was -$394.00K.
Period endIncrease (Decrease) in Accounts Payable and Accrued Liabilities 3 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 6 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 9 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 12 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 12 month as first filed
2025-12-31$434.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26
$1.16M
derived: sum of 2 quarters · filed 2026-03-26
$657.00K
derived: sum of 3 quarters · filed 2026-03-26
-$157.00K
10-K · filed 2026-03-26
2025-09-30$724.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
$223.00K
derived: sum of 2 quarters · filed 2025-11-06
-$591.00K
10-Q · filed 2025-11-06
-$267.00K
derived: sum of 4 quarters · filed 2026-03-26
2025-06-30-$501.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11
-$1.31M
10-Q · filed 2025-08-11
-$991.00K
derived: sum of 3 quarters · filed 2026-03-26
-$527.00K
derived: sum of 4 quarters · filed 2026-03-26
2025-03-31-$814.00K
10-Q · filed 2025-05-15
-$490.00K
derived: sum of 2 quarters · filed 2026-03-26
-$26.00K
derived: sum of 3 quarters · filed 2026-03-26
-$905.00K
derived: sum of 4 quarters · filed 2026-03-26
2024-12-31$324.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26
$788.00K
derived: sum of 2 quarters · filed 2026-03-26
-$91.00K
derived: sum of 3 quarters · filed 2026-03-26
-$1.02M
10-K · filed 2026-03-26
2024-09-30$464.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
-$415.00K
derived: sum of 2 quarters · filed 2025-11-06
-$1.34M
10-Q · filed 2025-11-06
-$952.00K
derived: sum of 4 quarters · filed 2025-11-06
2024-06-30-$879.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11
-$1.80M
10-Q · filed 2025-08-11
-$1.42M
derived: sum of 3 quarters · filed 2025-08-11
-$1.49M
derived: sum of 4 quarters · filed 2025-08-11
2024-03-31-$926.00K
10-Q · filed 2025-05-15
-$537.00K
derived: sum of 2 quarters · filed 2025-05-15
-$613.00K
derived: sum of 3 quarters · filed 2025-05-15
$501.00K
derived: sum of 4 quarters · filed 2025-05-15
2023-12-31$389.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14
$313.00K
derived: sum of 2 quarters · filed 2025-02-14
$1.43M
derived: sum of 3 quarters · filed 2025-02-14
$518.00K
10-K · filed 2025-02-14
2023-09-30-$76.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07
$1.04M
derived: sum of 2 quarters · filed 2024-11-07
$129.00K
10-Q · filed 2024-11-07
$1.12M
derived: sum of 4 quarters · filed 2024-11-07
2023-06-30$1.11M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08
$205.00K
10-Q · filed 2024-08-08
$1.19M
derived: sum of 3 quarters · filed 2024-08-08
$2.06M
derived: sum of 4 quarters · filed 2024-08-08
2023-03-31-$909.00K
10-Q · filed 2024-05-08
$80.00K
derived: sum of 2 quarters · filed 2024-05-08
$942.00K
derived: sum of 3 quarters · filed 2024-05-08
-$505.00K
derived: sum of 4 quarters · filed 2024-05-08
2022-12-31$989.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05
$1.85M
derived: sum of 2 quarters · filed 2024-03-05
$404.00K
derived: sum of 3 quarters · filed 2024-03-05
-$394.00K
10-K · filed 2024-03-05
2022-09-30$862.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14
-$585.00K
derived: sum of 2 quarters · filed 2023-11-14
-$1.38M
10-Q · filed 2023-11-14
-$1.60M
derived: sum of 4 quarters · filed 2023-11-14
2022-06-30-$1.45M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10
-$2.25M
10-Q · filed 2023-08-10
-$2.46M
derived: sum of 3 quarters · filed 2023-08-10
-$2.01M
derived: sum of 4 quarters · filed 2023-08-10
2022-03-31-$798.00K
10-Q · filed 2023-05-11
-$1.02M
derived: sum of 2 quarters · filed 2023-05-11
-$561.00K
derived: sum of 3 quarters · filed 2023-05-11
-$603.00K
derived: sum of 4 quarters · filed 2023-05-11
2021-12-31-$220.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30
$237.00K
derived: sum of 2 quarters · filed 2023-03-30
$195.00K
derived: sum of 3 quarters · filed 2023-03-30
-$1.92M
10-K · filed 2023-03-30
2021-09-30$457.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10
$415.00K
derived: sum of 2 quarters · filed 2022-11-10
-$1.70M
10-Q · filed 2022-11-10
$427.00K
derived: sum of 4 quarters · filed 2022-11-10
2021-06-30-$42.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11
-$2.15M
10-Q · filed 2022-08-11
-$30.00K
derived: sum of 3 quarters · filed 2022-08-11
$385.00K
derived: sum of 4 quarters · filed 2022-08-11
2021-03-31-$2.11M
10-Q · filed 2022-05-12
$12.00K
derived: sum of 2 quarters · filed 2022-05-12
$427.00K
derived: sum of 3 quarters · filed 2022-05-12
$436.00K
derived: sum of 4 quarters · filed 2022-05-12
2020-12-31$2.12M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24
$2.54M
derived: sum of 2 quarters · filed 2022-03-24
$2.55M
derived: sum of 3 quarters · filed 2022-03-24
-$702.00K
10-K · filed 2022-03-24
2020-09-30$415.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12
$424.00K
derived: sum of 2 quarters · filed 2021-11-12
-$2.82M
10-Q · filed 2021-11-12
-$5.36M
derived: sum of 4 quarters · filed 2021-11-12
2020-06-30$9.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12
-$3.24M
10-Q · filed 2021-08-12
-$5.77M
derived: sum of 3 quarters · filed 2021-08-12
-$4.69M
derived: sum of 4 quarters · filed 2021-08-12
2020-03-31-$3.25M
10-Q · filed 2021-05-11
-$5.78M
derived: sum of 2 quarters · filed 2021-05-11
-$4.70M
derived: sum of 3 quarters · filed 2021-05-11
-$6.31M
derived: sum of 4 quarters · filed 2021-05-11
2019-12-31-$2.54M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31
-$1.45M
derived: sum of 2 quarters · filed 2021-03-31
-$3.06M
derived: sum of 3 quarters · filed 2021-03-31
-$2.70M
10-K · filed 2021-03-31
$938.00K
10-K · filed 2020-03-25
2019-09-30$1.08M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10
-$530.00K
derived: sum of 2 quarters · filed 2020-11-10
-$162.00K
10-Q · filed 2020-11-10
$1.55M
derived: sum of 4 quarters · filed 2020-11-10
2019-06-30-$1.61M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14
-$1.25M
10-Q · filed 2020-08-14
$465.00K
derived: sum of 3 quarters · filed 2020-08-14
$1.87M
derived: sum of 4 quarters · filed 2020-08-14
2019-03-31$368.00K
10-Q · filed 2020-05-13
$2.08M
derived: sum of 2 quarters · filed 2020-05-13
$3.49M
derived: sum of 3 quarters · filed 2020-05-13
$5.02M
derived: sum of 4 quarters · filed 2020-05-13
2018-12-31$1.71M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25
$3.12M
derived: sum of 2 quarters · filed 2020-03-25
$4.65M
derived: sum of 3 quarters · filed 2020-03-25
$1.28M
10-K · filed 2020-03-25
2018-09-30$1.41M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07
$2.94M
derived: sum of 2 quarters · filed 2019-11-07
-$432.00K
10-Q · filed 2019-11-07
$1.70M
derived: sum of 4 quarters · filed 2019-11-07
2018-06-30$1.53M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09
-$1.84M
10-Q · filed 2019-08-09
$296.00K
derived: sum of 3 quarters · filed 2019-08-09
2018-03-31-$3.37M
10-Q · filed 2019-05-09
-$1.24M
derived: sum of 2 quarters · filed 2019-05-09
2017-12-31$2.14M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18
$195.00K
10-K · filed 2019-03-18
2017-09-30-$1.94M
10-Q · filed 2018-11-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
Onconetix, Inc. (ONCO)United States$0.004B
Sunshine Biopharma Inc. (SBFM)$0.003B
HCW Biologics Inc. (HCWB)United States$0.004B-6.15
REVELATION BIOSCIENCES, INC. (REVB)United States$0.004B
Alaunos Therapeutics, Inc. (TCRT)United States$0.003B-1.44
Genprex, Inc. (GNPX)United States$0.003B-0.02
Silo Pharma, Inc. (SILO)United States$0.003B-1.57
60 DEGREES PHARMACEUTICALS, INC. (SXTP)United States$0.004B-0.59
GeoVax Labs, Inc. (GOVX)United States$0.003B-0.45
Petros Pharmaceuticals, Inc. (PTPI)United States$0.003B